Abstract Hemoglobin-vesicles (Hb-V) are being developed as red blood cell (RBC)
substitutes. In this study, we report on quantitative and qualitative alterations of hepatic …

Patients who decline blood transfusion on the basis of religious belief, such as Jehovah's
Witnesses, pose unique management dilemmas and opportunities for healthcare. In …

Transfusion of erythrocytes (RBC) to treat acute or chronic anemia has significant
drawbacks, given the risks of transfusion, volunteer donor requirements, limited supply with …

Since the inception of the hemoglobin (Hb) program in 1989, the research at the Food and
Drug Administration (FDA) laboratories has focused on the role of oxidant-mediated …

This chapter traces the development of the use of erythrocyte transfusions, initially used with
greater attention to the dangers of anemia and less attention to the risks inherent in …

Hemoglobin-based oxygen carriers (HBOCs) are oxygen therapeutics that have been
available for critically ill severely anemic patients for whom blood is not an option through …

To overcome transfusion-associated problems, the development of artificial red blood cells
aims to provide an unlimited source of O 2 supply/CO 2 disposal as ready-to-use with any …

Artificial oxygen ca obtain a stable mixture. Perfluorocarbons rriers are classified into two
broad categories: hemoglobin-based and perfluorocarbon-based. Both provide oxygen …

The issues of practicality in using perfluorocarbon gas transport emulsions (or pure
perfluorocarbons) in severe virus-associated pneumonia treatment were considered …

We read with great interest the article by Mohanto et al. concerning reports on the medical
use of artificial oxygen carriers (AOS)[1]. We fully agree with the thesis that they may have …